Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHP607 for prevention of chronic lung disease in extremely premature infants
2018-001393-16Phase 2Unknown
- Sponsor
- Premacure
- Start
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mecasermin rinfabate in bronchopulmonary dysplasia (BPD) (3 arms), sponsored by Premacure. Primary endpoint: Time to final weaning off respiratory technology support. Status: unknown.
02
Drugs
mecasermin rinfabate
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on 2018-001393-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001393-16.